Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

IRB
CHLA-20-00294
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Adult Subjects with Classic Congenital Adrenal Hyperplasia, Followed by Open-Label Treatment

This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of NBI-74788 versus placebo administered bid with breakfast and the evening meal (doses separated by approximately 12 hours) for 24 weeks in approximately 165 adult subjects with classic CAH due to 21-hydroxylase deficiency.

Study Details
Clinical Trials Government Identifier
NCT04490915
Keywords
NBI-74788 Crinecerfont, CAH, Congenital Adrenal Hyperplasia, 21-hydroxylase deficiency, adult
Eligibility
Adults 18 years and older diagnosed with Classic Congenital Adrenal Hyperplasia
Does this study also recruit healthy volunteers?
No
Enrollment Status
Open
Coordinator Contact
Norma Martinez
Contact Email
nzmartinez@chla.usc.edu